The groundbreaking success of Viagra undeniably reshaped the drug landscape, but betting in companies primarily reliant on unbranded versions presents a challenging picture. Although early earnings were impressive, the end of patents and the rise of discounted alternatives have eroded sales. Consequently, a thorough evaluation of present income sou